Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.
This move brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to J&J’s oncology portfolio, supporting the development of oral, targeted therapies for several solid tumours, including prostate cancer.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition includes HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer. This therapy utilises the RIPTAC platform for precision targeting of cancer cells, aiming to address resistance mechanisms.
Additionally, the deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&J’s pipeline.
The company indicated that this platform could potentially enable the development of additional targeted therapies beyond oncology.
With the deal closing in 2025, J&J anticipates earnings dilution in the fourth quarter of 2025 and into 2026.
The total impact on adjusted earnings per share is expected to be around $0.20, divided equally between 2025 and 2026, reflecting charges related to Halda employee equity, financing, and integration costs.
J&J innovative medicine worldwide chairman and executive vice president Jennifer Taubert said: “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines.
“We are excited to formally welcome the talented Halda team to J&J and look forward to working together to achieve our shared goal of eliminating cancer.”
J&J innovative medicine R&D executive vice-president John Reed said: “Now that we have finalised this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond.”
In November 2025, J&J signed a definitive agreement for the acquisition of Halda.
